Test Overview
Direct immunofluorescence using flow cytometric techniques.
Evaluation of possible severe combined immunodeficiency. Testing is performed only on infants identified by State of Michigan TREC study as potential SCIDS patients. A full lymphoid cell panel is run, including B and T cell, T subsets, T-memory and naive subsets, and natural killer cell quantitation. Markers include:
-
CD3+
CD3+CD4+
CD3+CD8+
CD3-CD16/56+
CD19+
CD3+CD4+CD45RA+
CD3+CD4+CD45RO+
CD3+CD8+CD45RA+
CD3+CD8+CD45RO+
Calculated CD4:CD8 ratio (T4:T8 ratio)
* Reference ranges may change over time. Please refer to the original patient report when evaluating results.
Requires an adequate number of viable cells for analysis. Improper collection or transport may result in decreased cell viability and cancellation of testing.Specimen collection should be arranged so that specimen will be received Monday-Friday, 8:00 am - 4:30 pm. Refrigeration of specimens may result in the deterioration of surface markers.
- Absolute counts CANNOT be reported without accompanying CBCD.
Test Details
24 - 48 hours
- SCID (Severe Combined Immunodeficiency Disorder)
- Immunodeficiencies Profile, SCID
- Newborn Screen
- SCIDS PANEL
- SCIDS
- SCIDT
- SCID Panel Shadow
Specimen Requirements
Testing performed only for University of Michigan registered patients.